StockNews.AI
VEEV
StockNews.AI
7 days

Research Shows Medtechs Prioritizing Site Collaboration and Data Quality

1. 70% prioritize reducing manual processes in clinical trials. 2. Medtech companies face challenges in data entry and document exchange. 3. 58% of medtechs plan to optimize data collection in the next year. 4. 72% of organizations are investing in AI and ML solutions for data management. 5. Veeva supports clinical efficiency with solutions to streamline workflows.

7m saved
Insight
Article

FAQ

Why Bullish?

The focus on process optimization and AI investment suggests growth potential for VEEV.

How important is it?

The article highlights Veeva's role in an evolving sector, potentially increasing investor interest.

Why Long Term?

Ongoing investments in technology will enhance Veeva's market position over time.

Related Companies

MDLODGXEVGN
Nearly 70% say reducing manual processes is a key priority for working with sites, /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced findings from the 2025 Veeva MedTech Clinical Benchmark, showing that medtech clinical teams are focused on streamlining work with research sites to reduce manual processes (68%), improve study quality (56%), and gain greater visibility and oversight (55%). The findings emphasize an opportunity to leverage technology to simplify and standardize clinical workflows, work more effectively with sites, and speed trials. Medtech top drivers for optimizing clinical trial collaboration. Respondents identified on-time data entry and data quality, exchange of documents and data, and monitoring and compliance as the biggest challenges for site management. However, only 14% of medtechs with revenue over $1 billion and 24% with revenue under $1 billion have site collaboration tools in place, highlighting a gap as the industry moves toward improving trial efficiency and expediting study timelines. Additional insights about today's medtech clinical landscape from the benchmark report include: Manual processes increase risk. Reliance on manual processes (32%), complying with global trial regulation (18%), and inspection readiness (18%) were cited most often as the top hurdle in medtech clinical affairs. These high-risk areas can increase operational costs and cause significant trial delays. Process optimization efforts are underway. To maintain the integrity of clinical trials, 58% of medtechs plan to prioritize data collection and cleaning in the next year. By optimizing the data collection process, teams can spend less time on data reconciliation and focus on high-value trial activities. AI and ML initiatives are in early stages. Nearly three out of four medtech organizations (72%) are planning to invest in infrastructure for AI and ML solutions, working to harmonize existing systems and standardize data to make it AI-ready. "The medtech industry is driving initiatives to advance clinical processes, site collaboration, and data quality amidst economic pressures and new regulations," said Kevin Liang, vice president, clinical strategy, Veeva MedTech. "The report shows medtech companies are investing their efforts to ensure data integrity, improve operational efficiency, and drive connected processes across stakeholders to bring new technologies to patients faster."The 2025 Veeva MedTech Clinical Benchmark surveyed more than 100 clinical professionals at medical device and diagnostics companies. The report examines the current state of medtech clinical trials and how teams are working to modernize their operations. To learn more, read the full report.About Veeva MedTech Veeva MedTech helps medical device and diagnostics companies streamline the complete product development and commercialization lifecycles to deliver products to patients with greater speed and efficiency. Veeva MedTech's offering includes applications that advance clinical, regulatory, quality, commercial, and medical operations. For more information, visit veeva.com/medtech.About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.Veeva Forward-Looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at sec.gov.Contact:Deivis MercadoVeeva Systems[email protected]SOURCE Veeva Systems WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News